Substrate depletion approach for determining in vitro metabolic clearance: Time dependencies in hepatocyte and microsomal incubations

Drug Metabolism and Disposition

Volumn 32, Issue 9, 2004, Pages 973-982

  Jones, Hannah M ^a,b   Houston, J Brian ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b F Hoffmann La Roche ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; CHLORDIAZEPOXIDE; CLOBAZAM; CLONAZEPAM; DIAZEPAM; FLUNITRAZEPAM; MICROSOME ENZYME; MIDAZOLAM; PROTEIN; TRIAZOLAM;

ACCURACY; ANIMAL CELL; ARTICLE; CALCULATION; CELL DENSITY; CONCENTRATION RESPONSE; DRUG CLEARANCE; DRUG METABOLISM; INCUBATION TIME; LIVER CELL; LIVER CLEARANCE; LIVER MICROSOME; MALE; MEASUREMENT; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; RAT STRAIN; SUBSTRATE DEPLETION;

ANIMALS; ANTI-ANXIETY AGENTS; BENZODIAZEPINES; CARBON RADIOISOTOPES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; FORECASTING; HEPATOCYTES; MALE; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; PHARMACEUTICAL PREPARATIONS; RATS; RATS, SPRAGUE-DAWLEY; SUBSTRATE SPECIFICITY; TIME FACTORS;

ANIMALIA;

EID: 4143108324     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.000125     Document Type: Article

References (36)

1. Ashforth EI, Carlile DJ, Chenery R, and Houston JB (1995) Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data. J Pharmacol Exp Ther 274:761-766.
2. Ashley JJ and Levy G (1972) Inhibition of diphenylhydantoin elimination by its major metabolite. Res Commun Chem Pathol Pharmacol 4:297-306.
3. Austin RP, Barton P, Cockroft SL, Wenlock MC, and Riley RJ (2002) The influence of non-specific microsomal binding on apparent intrinsic clearance and its prediction from physiochemical properties. Drug Metab Dispos 30:1497-1501.
4. Carlile DJ, Stevens AJ, Ashforth EI, Waghela D, and Houston JB (1998) In vivo clearance of etboxycoumarin and its prediction from in vitro systems. Drug Metab Dispos 26:216-221.
5. Carlile DJ, Zomorodi K, and Houston JB (1997) Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes and the intact liver: studies with induced livers involving diazepam. Drug Metab Dispos 25:903-911.
6. Foti RS and Fisher MB (2004) Impact of incubation conditions on bufuralol human clearance predictions: enzyme lability and non-specific binding. Drug Metab Dispos 32:295-304.
7. Gerber N, Weller WL, Lynn R, Rangno RE, Sweetman BJ, and Bush MT (1971) Study of dose-dependent metabolism of 5,5-diphenylhydantoin in the rat using new methodology for isolation and quantitation of metabolites in vivo and in vitro. J Pharmacol Exp Ther 178:567-579.
8. Greenlee WF and Poland A (1978) An improved assay of 7-ethoxycoumarin O-deethylase activity: induction of hepatic enzyme activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2,3,7,8- tetrachlorodibenzo-p-dioxin. J Pharmacol Exp Ther 205:596-605.
9. Hayes KA, Brennan B, Chenery R, and Houston JB (1995) In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data. Drug Metab Dispos 23:349-353.
10. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
11. Houston JB and Carlile DJ (1997) Prediction of hepatic clearance from microsomes, hepatocytes and liver slices. Drug Metab Rev 29:891-922.
12. Houston JB, Kenworthy KE, and Galetin A (2003) Typical and atypical enzyme kinetics, in Drug Metabolizing Enyzmes. Cytochrome P450 and Other Enzymes in Drug Discovery and Development (Lee JS, Obach RS, and Fisher MB eds) pp 211-254, Fontis Media, Lausanne, Switzerland and Marcel Dekker, New York.
13. Ito K and Houston JB (2004) Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm Res (NY) 21:785-792.
14. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171.
15. Jones HM, Hallifax D, and Houston JB (2004) Quantitative prediction of the in vivo inhibition of diazepam metabolism by omeprazole using rat liver microsomes and hepatocytes. Drug Metab Dispos. 32:572-580.
16. Khan KK, He YQ, Domanaski TL, and Halpert JR (2002) Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol Pharmacol 6t:495-506.
17. Kobayashi K, Urashima K, Shimada N, and Chiba K (2002) Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. Biochem Pharmacol 63:889-896.
18. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, and Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89-96.
19. Lavé TH, Dupin S, Schmitt C, Valles B, Ubead G, Chou RC, Jaeck D, and Coassolo PH (1997) The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm Res (NY) 14:152-155.
20. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
21. Madan A, Usuki E, Burton LA, Ogilvie BW, and Parkinson A (2002) In vitro approaches for studying the inhibition of drug-metabolising enzymes and identifying the drug-metabolising enzymes responsible for the metabolism of drugs, in Drug-Drug Interactions (Rodrigues A ed) pp 217-293, Marcel Dekker, Inc., New York.
22. McGinnity DF and Riley RJ (2001) Predicting drug pharmacokinetics in humans from in vitro metabolism studies. Biochem Soc Trans 29:135-139.
23. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
24. Obach RS (2001) The prediction of human clearance from hepatic microsomal data. Curr Opin Drug Discov Dev 4:36-44.
25. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
26. Obach RS and Reed-Hagen AE (2002) Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using the substrate depletion approach. Drug Metab Dispos 30:831-837.
27. Pang KS and Gillette JR (1978) Complications in the estimation of hepatic blood flow in vivo by pharmacokinetic parameters. Drug Metab Dispos 6:567-576.
28. Podoll TD, Kunze KL, Thummel KE, Fisher JM, and Trager WF (1995) Evidence supporting mechanism-based inactivation of CYP 3A by midazolam, ISSX Proc 8:154.
29. Pollack GM, Brouwer KLR, Demby KB, and Jones JA (1999) Determination of hepatic blood flow in the rat using sequential infusions of indocyanine green or galactose. Drug Metab Dispos 18:197-202.
30. Savenije-Chapel EM, Bast A, and Noordheek J (1985) Inhibition of diazepam metabolism in microsomal and perfumed liver preparations of the rat by desmethyldiazepam, N-methyloxazepam and oxazepam. Eur J Drug Metab Pharmacokinet 10:15-20.
31. Schrag ML and Wienkers LC (2001) Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains. Arch Biochem Biophys 391:49-55.
32. Steinberg P, Fischer T, Kiulies S, Biefang K, Platt KL, Oesch F, Bottger T, Bulitta C, Kempf P, and Hengstler J (1999) Drug metabolizing capacity of cryopreserved human, rat, and mouse liver parenchymal cells in suspension. Drug Metab Dispos 27:1415-1422.
33. Suzuki A, Iida I, Tanaka F, Akimoto M, Fukushima K, Tani M, Ishizaki T, and Chiba K (1999) Identification of human cytochrome P-450 isoforms involved in metabolism of R(+)- and S(-)-gallopamil: utility of in vitro disappearance rate. Drug Metab Dispos 27:1254-1259.
34. Venkatakrishnan K, von Moltke LL, Obach RS, and Greenblatt DJ (2000) Microsomal binding of amitriptyline: effect on estimation of enzyme kinetic parameters in vitro. J Pharmacol Exp Ther 293:343-350.
35. Witherow LE and Houston JB (1999) Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat. J Pharmacol Exp Ther 290:58-65.
36. Zomorodi K, Carlile DJ, and Houston JB (1995) Kinetics of diazepam metabolism in rat hepatic microsomes and hepatocytes and their use in predicting in vivo hepatic clearance. Xenobiotica 25:907-916.